Google has suspended business activity involving the transfer of hardware, software and key technical services with Huawei. Analysts say that could be a big blow to the...Technologyread more
Huawei Technologies will immediately lose access to updates to the Android operating system, a source close the matter told Reuters.Technologyread more
Huawei claims it has developed its own operating system for smartphones and laptops for "extenuating circumstances."Technologyread more
Current geopolitical tensions are making it harder and harder for oil-producing nations to make decisions that will help stabilize crude prices, Russian Energy Minister...Oilread more
Oil prices jumped on Monday after Saudi Energy Minister Khalid al-Falih indicated there was a consensus among OPEC and allied oil producers to continue limiting supply.Energyread more
Bank, property and healthcare stocks jumped, pushing Australian markets to a 11-year high, as Scott Morrison and the Liberal-led conservation government are poised for a...World Marketsread more
Trump's threat, posted on Twitter, comes amid rising international tensions in the Middle East as the U.S. has dispatched a carrier strike group and bomber task force to the...Politicsread more
Prime Minister Narendra Modi and his Bharatiya Janata Party are set to form the new government again, exit polls from India's month-long parliamentary elections show. But past...Electionsread more
The latest crisis in the uneasy French-German relationship was accelerated by Trump's decision to stop Germany's comfortable and decades-old free-riding on trade and security...Europe Politicsread more
While some fans of the long-running "Game of Thrones" felt satisfied by the show's final bow, others were quick to express their displeasure with how events unfolded.Entertainmentread more
Stocks in Asia were mixed on Monday amid a series of geopolitical developments across the region.Asia Marketsread more
Executives from seven pharmaceutical manufacturers will testify about drug pricing practices before the Senate Finance Committee "one way or another," Sen. Ron Wyden, D-Ore., said Tuesday.
Wyden and Sen. Chuck Grassley, R-Iowa, on Monday sent letters asking for representatives from the seven major drugmakers to testify at a Feb. 26 hearing. The seven companies are AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi.
Calling the pace of drug price increases "unsustainable," Grassley, who is the committee's chairman, said in a statement that he wants pharmaceutical executives to explain how they price these treatments, "whether the status quo is unacceptable" and what can be done to lower costs.
Wyden, the committee's ranking member, followed with a tweet Tuesday that stopped short of threatening to issue a subpoena, indicating that participation at the hearing isn't entirely voluntary. He said the companies "will come before the committee one way or another."
Grassley criticized pharmaceutical companies that declined his invitation to testify at last week's hearing about drug prices, adding that several of the companies asked to testify Feb. 26 declined his original request.
"The companies that declined said they would discuss their ideas in private, but not in public," Grassley said at the committee's Jan. 29 hearing. "That is not what I mean when I talk about transparency. So, we will extend the opportunity again in the future, but we will be more insistent the next time."
Wyden said at the time that the committee would use its "power to compel the drug company CEOs to show up" if they don't testify.
Two companies have agreed to send their CEOs to the hearing, a spokeswoman for Grassley said Tuesday. Merck CEO Ken Frazier will attend, a spokeswoman for the company told CNBC. Sanofi is determining whether current scheduling allows CEO Olivier Brandicourt to attend the hearing, a spokeswoman said. AstraZeneca told CNBC that "we are currently reviewing the request and will respond to the Committee in due course."
Lawmakers on both sides of the aisle have demanded something be done to lower drug prices. President Donald Trump has made lowering out-of-pocket costs for patients one of his administration's top priorities. He's expected to address the issue Tuesday night in his State of the Union address.